HeartBeam Expands Board with CEO Robert Eno's Appointment

Medical technology company HeartBeam Inc. has strengthened its leadership team by appointing Chief Executive Officer Robert Eno to its Board of Directors. The move expands the board from eight to nine members and underscores the company's commitment to advancing personalized cardiac care technology.

Eno, who initially joined HeartBeam as president in January 2023 and became CEO in October 2024, brings over three decades of medtech leadership experience to the role. His extensive background includes successfully launching disruptive technologies in the medical technology sector.

The appointment comes at a critical juncture for HeartBeam, as the company prepares for the commercial launch of its groundbreaking 3D ECG technology. Pending FDA clearance of its 12-lead ECG synthesis software, the company is poised to revolutionize cardiac health monitoring.

HeartBeam's platform technology represents a significant advancement in cardiac care, offering the first cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This innovative approach enables physicians to identify cardiac health trends and acute conditions outside traditional medical facilities.

The company's technological innovation is protected by an impressive portfolio of 13 U.S. and 4 international patents, highlighting the potential transformative impact of their cardiac monitoring solution. By enabling portable cardiac diagnostics, HeartBeam aims to provide actionable heart intelligence wherever patients are located.

Eno's board appointment signals the company's strategic vision to leverage experienced leadership in bringing advanced cardiac monitoring technologies to market. His deep understanding of medtech innovation positions HeartBeam to potentially reshape how cardiac health is monitored and managed.